Navigation Links
China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
Date:9/19/2008

SHANGHAI, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) (''China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, announced today that at its 2008 Annual General Meeting of Shareholders (the ''AGM''), stockholders re-elected all of the Company's nominees to the Board of Directors.

At the meeting, held September 12, 2008, shareholders approved the re-election of Mr. Jinan Song, Dr. Ji Wei Chin, Dr. Wen Min Du and Mr. Simon Yick as members of the Company's Board of Directors. Shareholders also ratified the appointment of BDO McCabe Lo Limited as the Company's independent auditors for the fiscal year ending March 31, 2008.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company''), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the ''Shining'' brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

CCG Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgirasia.com


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
5. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
6. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. China-Biotics, Inc. Completes Foundation for Its New Plant
9. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
10. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
11. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... Calvert Labs, Inc. announced today that ... Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. in Pharmacology ... an academic and industry preclinical drug developer spans more than three decades. ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and ... under which Nipro will receive exclusive marketing and sales rights for all non-OEM Transonic ... for hemodialysis patients in Japan, the new Nipro - Transonic JV is a natural ...
(Date:1/21/2017)... 21, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, today presented data from two ... the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal ... In a Phase Ib/II study of ... inhibit cancer stemness pathways by targeting STAT3 – colorectal ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Surgery (LES®) Technologies, announced today the next evolution in spinal fusion, the ... platform). In contrast to the competition, SpineFrontier is focused on technique driven ...
Breaking Biology Technology:
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
Breaking Biology News(10 mins):